The current contribution of molecular factors to risk estimation in neuroblastoma patients

The association of molecular characteristics with prognosis has been reported, but not their relationship with each other and their impact in the context of known clinical risk factors. In this study, data of 1249 consecutive intent-to-treat-neuroblastoma patients with more than 1 year follow-up were examined by multivariate analysis using loglinear and Cox proportional hazard regression models on a stage-related basis (stages 1–3: 600, 4S: 116, 4: 533). In a first step, risk factors were identified from 18 selected clinical variables, and risk groups defined. The second step investigated whether molecular characteristics ( MYC N, LOH 1p, del 1p, CD44, N- ras, NGF-R, bcl-2, APO-1 (CD95)) contributed additional prognostic information to the model. The loglinear model demonstrated several interactions between clinical factors. By the Cox regression model, seven independent clinical risk factors were found for stages 1–3, seven for stage 4 and two for stage 4S. By subsequent introduction of all molecular variables, MYC N amplification only added significant prognostic information to the clinical factors in localised and stage 4 neuroblastoma. The models allowed the definition of risk groups for stages 1–3 patients by age ( eβ = 5.09) and MYC N ( eβ = 4.26), for stage 4 by MYC N ( eβ = 2.78) and number of symptoms ( eβ = 2.44) and for stage 4S by platelet count ( eβ = 3.91) and general condition ( eβ = 2.99). Molecular factors and in particular MYC N contribute significantly to risk estimation. In conjunction with clinical factors, they are powerful tools to define risk groups in neuroblastoma.